Depression, sleep disturbance, and quality of life in patients undergoing dialysis therapy
Abstract
AIMS: To examine the association between depression, excessive daytime sleepiness (EDS), and quality of life (QOL) in patients undergoing dialysis.
BACKGROUND: Sleep disturbance and depression are highly prevalent symptoms in patients on dialysis and are associated with poor clinical outcomes. Nevertheless, the complex association between EDS and depression in patients on dialysis and the determination of which of the two has a greater impact on QOL are not well documented.
METHODS: This study used a correlational cross-sectional design. A convenience sample of 180 patients on dialysis was surveyed using the Beck Depression Inventory-II (BDI-II), Epworth Sleepiness Scale (ESS), and the short version of the Kidney Disease Quality of Life. Multiple regression analyses were performed to assess the predictors of QOL.
RESULTS: The overall mean total QOL score was 52.13 ± 19.22. The mean scores of depression and EDS were 16.36 ± 9.95 and 7.544 ± 531, respectively. Considering cut-off scores of ≥11 for BDI-II and ≥10 for ESS, 5.6 % of the participants had depression and 32.2 % had EDS. Depression was independently associated with a lower QOL score (r = -0.57, p < 0.001). The model showed a 38 % variation in the total QOL score.
CONCLUSIONS: Depression and EDS were high among patients on dialysis, and depression was the main predictor of QOL. Screening for these unpleasant symptoms using brief and proven methods should be included in the standard clinical practice.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 180 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.